Prostate Cancer Clinical Trials in San Francisco, California

26 studies are recruiting for prostate cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

   To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   23 in total

   Run by

   Axonics, Inc.

   See if you can join NCT06511141 on ClinicalTrials.gov

2. Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

   This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT05766371 on ClinicalTrials.gov

3. Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

   There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of ac…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Thomas Hope

   See if you can join NCT07054346 on ClinicalTrials.gov

4. COMPASS Study for Metastatic Castration-resistant Prostate Cancer

   This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more abo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   4 in total

   Run by

   Duke University

   See if you can join NCT07050433 on ClinicalTrials.gov

5. Precision-Based Genomics in Prostate Cancer

   Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   University of California San Francisco, San Francisco, California

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04706663 on ClinicalTrials.gov

6. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

7. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

8. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   36 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

9. A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

   ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, San Francisco, California

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07336446 on ClinicalTrials.gov

10. Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

    The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    9 in total

    Run by

    Amgen

    See if you can join NCT06613100 on ClinicalTrials.gov

11. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #111, San Francisco, California

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

12. PSMA PET Combined With MRI for the Detection of PCa

    This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    18 in total

    Run by

    Telix Pharmaceuticals (Innovations) Pty Limited

    See if you can join NCT07052214 on ClinicalTrials.gov

13. Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

    Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening er…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT07690579 on ClinicalTrials.gov

14. Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

    This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    2 in total

    Run by

    David Oh

    See if you can join NCT03821246 on ClinicalTrials.gov

15. 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastase…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT07145177 on ClinicalTrials.gov

16. Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

    This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT03933670 on ClinicalTrials.gov

17. Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

    This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCSF, San Francisco, California

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT05948657 on ClinicalTrials.gov

18. Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

    This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Ivan de Kouchkovsky, MD

    See if you can join NCT02526368 on ClinicalTrials.gov

19. Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

    The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06171139 on ClinicalTrials.gov

20. Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

    This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation t…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Kaiser Permanente-San Francisco, San Francisco, California

    Locations

    57 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT06235697 on ClinicalTrials.gov

21. Mechanisms of Resistance to PSMA Radioligand Therapy

    This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    3 in total

    Run by

    University of California, San Francisco

    See if you can join NCT05435495 on ClinicalTrials.gov

22. 64Cu-GRIP B in Patients With Advanced Malignancies

    This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patie…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Rahul Aggarwal

    See if you can join NCT05888532 on ClinicalTrials.gov

23. Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

    This clinical trial explores and implements methods to improve informed decision making (IDM) regarding precision oncology tests amongst veterans with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Precision o…

    Stage

    Not phased

    Ages

    18 and older

    Site

    San Francisco Veterans Affairs Medical Center, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT05396872 on ClinicalTrials.gov

24. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Francisco, San Francisco, California

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

25. Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

    This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Robert Bok, MD, PhD

    See if you can join NCT06391034 on ClinicalTrials.gov